Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co. KGaA

FMS

$22.35

Updated: 25/09/2026, 01:57:53

Market Cap
$12.00B
Sector
Healthcare
Industry
Medical - Care Facilities
Country
DE
Stock valuation chart
One-year closing share-price history for FMS
Company Profile

Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.

USD
NYSE
CEO: Helen Giza
Employees: 108,165
https://www.freseniusmedicalcare.com
Asset Summaries
Latest generated summaries for FMS

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for FMS.
Share price
$22.35
Market cap
$12.00B
Exchange
NYSE
Currency
USD
CEO
Helen Giza
Employees
108,165
IPO date
17/09/1996
Beta
0.739
Last dividend
$0.00
Day range
$22.19 – $22.44
52-week range
$20.02 – $27.64
1-day performance
-0.27%
1-year performance
11.64%
Current drawdown (1Y)
-19.14%
CIK
0001333141
CUSIP
358029106
ISIN
US3580291066
Created
07/12/2025, 04:02:54
Last update
25/09/2026, 01:57:53

Track Fresenius Medical Care AG & Co. KGaA with an AI analyst

See which prediction-market events move FMS, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.